A Phase I, First-in-human, Open-label, Dose Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-1287 to Patients With Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 17 Mar 2019
Price : $35 *
At a glance
- Drugs TP 1287 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Tolero Pharmaceuticals
- 10 Jan 2019 According to a Tolero Pharmaceuticals media release, the first patient has been dosed in this study.
- 20 Dec 2018 Status changed from not yet recruiting to recruiting.
- 15 Oct 2018 Planned initiation date changed from 1 Aug 2018 to 1 Oct 2018.